Individuals with myasthenia gravis (MG) lived 15 to 19 years longer than those with multiple sclerosis (MS), across 4 ...

Hepatitis B elimination requires expanded vaccination, screening, treatment, and education, Helen Nde, MPH, said. Nde framed ...

Population Health, Equity & Outcomes is a quarterly publication dedicated to providing a platform for the exchange of research, policy analysis, and insights that aim to improve health outcomes and ...

MINT randomized 238 patients to inebilizumab 300 mg IV vs placebo with a protocol-driven taper to prednisone ≤5 mg/day and ...

FDA approves brepocitinib, the first oral, targeted therapy for adult dermatomyositis, backed by phase 3 VALOR data. For the ...

Children and young adults who were unvaccinated and infected with COVID-19 were at an increased risk of developing ...

Transplant weight-loss access, a new dermatomyositis drug, mifepristone safety views, and racial gaps in cataract surgery and ...

Tirzepatide is now approved to lower cardiovascular death, heart attack, or stroke risk in adults with type 2 diabetes.

FDA has approved rusfertide, a groundbreaking therapy that promises to spare patients with polycythemia vera (PV) repeated phlebotomies, the agency and officials from Takeda and P ...

Zidesamtinib offers a new second-line option for ROS1-positive NSCLC, with durable responses and strong activity against brain metastases.

The findings reinforce monitoring and managing thrombotic risk across the PV population rather than focusing on traditionally ...

T-cell therapy has transformed outcomes in several blood cancers, but its success is far from uniform. According to Kerry ...